380 related articles for article (PubMed ID: 29298899)
21. Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation.
Aliwarga T; Dinh JC; Heyward S; Prasad B; Gharib SA; Lemaitre RN; Sotoodehnia N; Totah RA
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293289
[TBL] [Abstract][Full Text] [Related]
22. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model.
Batchu SN; Law E; Brocks DR; Falck JR; Seubert JM
J Mol Cell Cardiol; 2009 Jan; 46(1):67-74. PubMed ID: 18973759
[TBL] [Abstract][Full Text] [Related]
23. Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response.
Nayeem MA; Geldenhuys WJ; Hanif A
Adv Pharmacol; 2023; 97():37-131. PubMed ID: 37236764
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling.
Merkel MJ; Liu L; Cao Z; Packwood W; Young J; Alkayed NJ; Van Winkle DM
Am J Physiol Heart Circ Physiol; 2010 Feb; 298(2):H679-87. PubMed ID: 20008276
[TBL] [Abstract][Full Text] [Related]
25. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia.
Zhang W; Otsuka T; Sugo N; Ardeshiri A; Alhadid YK; Iliff JJ; DeBarber AE; Koop DR; Alkayed NJ
Stroke; 2008 Jul; 39(7):2073-8. PubMed ID: 18369166
[TBL] [Abstract][Full Text] [Related]
26. Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells.
Katragadda D; Batchu SN; Cho WJ; Chaudhary KR; Falck JR; Seubert JM
J Mol Cell Cardiol; 2009 Jun; 46(6):867-75. PubMed ID: 19285984
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation.
Deng Y; Theken KN; Lee CR
J Mol Cell Cardiol; 2010 Feb; 48(2):331-41. PubMed ID: 19891972
[TBL] [Abstract][Full Text] [Related]
28. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.
Ng VY; Huang Y; Reddy LM; Falck JR; Lin ET; Kroetz DL
Drug Metab Dispos; 2007 Jul; 35(7):1126-34. PubMed ID: 17431031
[TBL] [Abstract][Full Text] [Related]
30. Reduced coronary reactive hyperemia in mice was reversed by the soluble epoxide hydrolase inhibitor (t-AUCB): Role of adenosine A
Hanif A; Edin ML; Zeldin DC; Morisseau C; Falck JR; Ledent C; Tilley SL; Nayeem MA
Prostaglandins Other Lipid Mediat; 2017 Jul; 131():83-95. PubMed ID: 28890385
[TBL] [Abstract][Full Text] [Related]
31. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
Chen G; Xu R; Wang Y; Wang P; Zhao G; Xu X; Gruzdev A; Zeldin DC; Wang DW
Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E563-75. PubMed ID: 22739108
[TBL] [Abstract][Full Text] [Related]
32. sEH promotes macrophage phagocytosis and lung clearance of Streptococcus pneumoniae.
Li H; Bradbury JA; Edin ML; Graves JP; Gruzdev A; Cheng J; Hoopes SL; DeGraff LM; Fessler MB; Garantziotis S; Schurman SH; Zeldin DC
J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34591792
[TBL] [Abstract][Full Text] [Related]
33. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice.
Luria A; Weldon SM; Kabcenell AK; Ingraham RH; Matera D; Jiang H; Gill R; Morisseau C; Newman JW; Hammock BD
J Biol Chem; 2007 Feb; 282(5):2891-8. PubMed ID: 17135253
[TBL] [Abstract][Full Text] [Related]
34. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.
Liu Y; Webb HK; Fukushima H; Micheli J; Markova S; Olson JL; Kroetz DL
J Pharmacol Exp Ther; 2012 Jun; 341(3):725-34. PubMed ID: 22414856
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.
Chaudhary KR; Abukhashim M; Hwang SH; Hammock BD; Seubert JM
J Cardiovasc Pharmacol; 2010 Jan; 55(1):67-73. PubMed ID: 19834332
[TBL] [Abstract][Full Text] [Related]
36. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
37. Soluble epoxide hydrolase: a new target for cardioprotection.
Gross GJ; Nithipatikom K
Curr Opin Investig Drugs; 2009 Mar; 10(3):253-8. PubMed ID: 19333883
[TBL] [Abstract][Full Text] [Related]
38. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice.
Hercule HC; Schunck WH; Gross V; Seringer J; Leung FP; Weldon SM; da Costa Goncalves ACh; Huang Y; Luft FC; Gollasch M
Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):54-60. PubMed ID: 18927469
[TBL] [Abstract][Full Text] [Related]
39. Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure.
Sun D; Cuevas AJ; Gotlinger K; Hwang SH; Hammock BD; Schwartzman ML; Huang A
Am J Physiol Heart Circ Physiol; 2014 Apr; 306(8):H1146-53. PubMed ID: 24561863
[TBL] [Abstract][Full Text] [Related]
40. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.
Shahabi P; Siest G; Visvikis-siest S
Drug Metab Rev; 2014 Feb; 46(1):33-56. PubMed ID: 24040964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
